Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

MRC and AstraZeneca Scoop Prestigious SCRIP Award

Published: Tuesday, December 04, 2012
Last Updated: Tuesday, December 04, 2012
Bookmark and Share
The innovative collaboration between the Medical Research Council and AstraZeneca has won the ‘Best Partnership Alliance’ award at the annual SCRIP Awards.

The AZ-MRC alliance broke new ground in the way industry collaborates with academia and government to share knowledge and discover and develop new drugs.

Clive Morris, AstraZeneca Vice President, New Opportunities iMed, said:

“We are deeply honoured that our alliance with the MRC has been singled out for its innovative character. This is especially meaningful because our alliance with the MRC has played a leading role in inspiring a new era of collaboration and open innovation in the industry.”

Dr Chris Watkins, Head of Translational Research and Industry Liaison at the MRC, who accepted the award, said:

"It's been an absolute pleasure to work with AstraZeneca throughout our ground-breaking compound collaboration and we feel we've made a real step forward in the way we collaborate with industry. We were really pleased with the quality of science we funded through the partnership and to have this all recognised by a prestigious SCRIP award is the icing on the cake, we're delighted to have won."

SCRIP is one of the world’s leading pharmaceutical and biotech news organisations and its ‘Best Partnership Alliance’ award recognises the importance of partnerships involving pharmaceutical and/or biotech companies in developing novel therapeutics.

The ceremony, which took place on 28 November at London’s Lancaster Hotel, rewarded excellence over the whole range of industry activities, from pharma, biotech and those companies that support them.

The AZ-MRC alliance, in which 22 previously studied AstraZeneca compounds were made available to academic researchers, was announced in December 2011. Since then, the MRC and AstraZeneca have announced £7 million funding for 15 research projects involving those compounds.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

MRC, GSK and Five Leading UK Universities Collaborate
Collaboration to crack difficult disease areas.
Thursday, July 16, 2015
MRC and Wellcome Trust Invest £24m in Cambridge Obesity Institute
The joint venture provides a unique environment linking basic and applied science in metabolic diseases.
Thursday, May 30, 2013
Brain Chemical Finding could Open Door to new Schizophrenia Drugs
New research has linked psychosis with an abnormal relationship between two signalling chemicals in the brain.
Friday, October 01, 2010
International Collaboration Brings Stem Cell Clinical Trials a Step Closer
Funding for two ambitious projects aimed at bringing stem cell treatments to the point of clinical trial has been unveiled by the Medical Research Council (MRC) today.
Friday, October 30, 2009
MRC welcomes new blueprint for life sciences
A new Blueprint to put innovation at the heart of healthcare delivery in the UK has been launched by Lord Drayson and Lord Darzi at Imperial College London.
Wednesday, July 15, 2009
New Institute to Study Obesity, Diabetes and Other Metabolic Disorders
A new centre has opened to address the growing threat to public health posed by obesity, diabetes and related diseases. The University of Cambridge, the Medical Research Council and Cambridge University Hospitals NHS Foundation Trust have joined forces to create the unique, innovative Institute of Metabolic Science (IMS).
Friday, August 29, 2008
Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos